Compare Incyte Corporation (INCY) vs Match Group Inc (MTCH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Match Group Inc — how do they compare? Incyte Corporation trades at $120.77 (market cap $24.54B), while Match Group Inc trades at $36.82 (market cap $8.45B). The key difference: Incyte Corporation is far larger — about 2.9× Match Group Inc's market cap, and Match Group Inc pays a 2.17% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | MTCH | |
|---|---|---|
Market Cap | $24.54B | $8.45B |
Sector | Health | Media |
52-Week High | $129.93 | $41.24 |
52-Week Low | $81.61 | $28.90 |
Enterprise Value | $20.04B | $11.42B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Match Group (MTCH) trades at $36.63, down 0.27% with bearish technical signals despite reasonable valuation metrics (P/E 13.05, P/S 2.66). Recent Q2 2026 earnings missed revenue estimates with $853 million (down 1% YoY) though Tinder engagement improved and Hinge grew 22% YoY. Operating cash flow remains strong at $1.08 billion in 2025, but high debt ($3.85 billion) and negative shareholder equity pose balance sheet concerns.
The outlook is mixed: analyst consensus is Buy (53% of 32 analysts) with $42.33 price target (16% upside), but near-term revenue pressure and Tinder's sluggish performance create headwinds. Investment opportunity lies in Hinge's international expansion and Tinder turnaround potential, while risks include execution missteps, competitive threats, and macroeconomic sensitivity affecting dating app usage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
